ARTICLE | Clinical News
CP024: Phase I data
February 18, 2013 8:00 AM UTC
Critical Pharmaceuticals reported data from a Phase I trial in 7 healthy volunteers showing that 2-6 mg doses of intranasal CP024 plus an infusion of octreotide "strongly" induced the production of in...